

Pharmacy and Therapeutics Committee Meeting
May 13th, 2003
Kellogg Hotel and Conference Center

Draft Minutes

Committee Members in Attendance:

David Johnson, M.D., Chairman
Giovanini Perri, M.D.
Robert Coffey, PharmD
Debra Eggleston, M.D.
Robert Ernst, M.D.
Edward Keating, RPh
Max Robins, D.O.

Not in Attendance:

Sandra Campbell, PharmD
Jonathon Henry, M.D.

State of Michigan Representatives in Attendance:

Doris R. Gellert, Director, Pharmacy, Medical and Beneficiary Services Bureau
Paul Reinhart, Deputy Director, Medical Services Administration
George Baker, M.D., Office of Medical Affairs
Brad Sprecher, Pharmacy, Medical and Beneficiary Services Bureau

First Health Services Corporation Representatives in Attendance:

Annette Paul, Medicaid Clinical Manager
Bruce Edgren, Sr. Director Clinical Program Development

Audience:

Approximately 70 members of the public, including physicians and drug company representatives, were in attendance.

- I. The meeting is called to order at 6:15 p.m. by Dr. David Johnson
- II. Deputy Director for the Medical Services Administration, Paul Reinhardt, announces that CMS has approved the multi-state purchasing plan for drug products.

- III. Dr. Johnson moderates the public comments, from the following constituencies (in the order of presentation):

Dr. Aajay Shah, Cardiologist: Medication choices for Beta Blockers
GlaxoSmithKline: Dan Keeney and Dr. Birgit Amann
Eli Lilly: Danielle Loosbrock
Merck & Co.: Dr. David Neff
Bristol-Myers Squib: Robert Jankowski (in place of Dr. Jennifer Meredith)

- IV. Bruce Edgrin, of First Health Services Corporation, provides an overview of the multi-state purchasing program to date.

- V. The Committee reviews current and proposed drug classes for inclusion on the Preferred Drug List (PDL). Discussion is guided by the P&T subgroup recommendations.

The Committee accepts the recommendations of the P&T work-groups with regards to the selection of generics in several categories, with no preference for branded products. Those categories are as follows:

Direct Acting Sympathomimetics – Glaucoma (New PDL category)
Cholinergic Agonists – Glaucoma (New PDL category)
Analgesic NSAIDs – with consideration to children

Antibiotics – Cephalosporins 1st Generation
Antibiotics – Cephalosporins 2nd Generation
Topical Antifungals – Dermatologics
Lipotropics – BARs
Lipotropics – Fibric Acid Derivatives
Lipotropics – Niacin Derivatives
Beta Blockers
Calcium Channel Blockers – Non-dihydropyridines
ACE Inhibitors
ACE Inhibitor/Diuretic Combinations
Coronary Vasodilators (oral)
Coronary Vasodilators (topical)
Glucocorticoids – systemic
Histamine 2 Receptor Antagonists
Sulfoinylureas (Diabetes)
Hypoglycemics – Biguanide type
Beta-Adrenergic Agents: Nebulizers
Topical Steroids

The Committee accepts the recommendations of the P&T subgroups, which include preference for some branded products for the following categories:

Third Generation Cephalosporins (New PDL category): consideration to children

Serotonin Receptor Agonists (New PDL category): with grandfathering consideration, including PA

Angiotensin Receptor Blockers – as second-line agents

Angiotensin Receptor Blockers and Diuretics – as second-line agents

Antiemetics – Oral (New PDL category): with grandfathering consideration, including PA

Alpha 2 Adrenergic Agents – Glaucoma (New PDL entities): as 2nd/3rd line agents

Beta Blockers – Glaucoma (New PDL entities)

Carbonic Anhydrase Inhibitors – Glaucoma (New PDL entities): consideration to children; not first-line

Prostaglandin Agonists – Glaucoma (New PDL entities)

Leukotriene Modifiers (New PDL category): grandfathering and consideration to children

Hepatitis C (New PDL category): with grandfathering consideration

Narcotics: various potencies

Macrolides: adult

Macrolides: pediatric, with considerations

Second Generation Quinolones (systemic)

Third Generation Quinolones (systemic)

Oral Antifungals: Nononychomycosis

Oral Antifungals: Onychomycosis, with limitations

Statins: with consideration to additional subgroups

Lipotropics: other

Herpes Antivirals

Influenza Antivirals

ACE Inhibitor/Calcium Channel Blocker combinations

Biguanide Combination Oral Anti-Diabetics: with clinical considerations,
considerations to grandfathering

Inhaled Corticosteroids (with consideration to a subclass on clinical
grounds)

Insulins

Nasal Steroids

Osteoporosis Agents

Osteoporosis Agents – other

Platelet Inhibitors: with grandfathering consideration

The Committee accepts the recommendations of the P&T subgroups for the following
categories, with amendments:

Narcotics: Long Acting

COX II Inhibitors: with a consideration to clinical edits

Second Generation Cephalosporins

Low-Sedating Antihistamines

Calcium Channel Blockers: Dihydropyridines

Proton Pump Inhibitors: with a consideration to children

Thiazolidinedione Antidiabetics: with a consideration to grandfathering

Alpha-glucosidase Inhibitor Antidiabetics: with a consideration to grandfathering

Meglitinide Antidiabetics: with a consideration to grandfathering

Short-Acting Beta Adrenergics (asthma)

Long-acting Beta Adrenergic agents (asthma)

Low Sedating Antihistamines/Decongestant Combinations: with coverage
considerations

VI. Meeting adjourns at 9:25 p.m.

**Next meeting is June 3, 2003
6:00-9:00 p.m.**

Kellogg Hotel and Conference Center

Respectfully submitted by Bradley S. Sprecher